Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 183

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 183
---
The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.The following weighted average assumptions were used to value options granted during the periods indicated:

        Year Ended December 31, 2024

        Year Ended December 31, 2023

        Expected term
        5.94 years

        5.98 years

        Expected volatility
         
        110.6
        %

        90.8
        %

        Risk-free interest rate
         
        4.28
        %

        4.04
        %

        Expected dividend yield
         
        —

        —

F-20

AN2 Therapeutics, Inc.Notes to Financial Statements — Continued 

Stock Option Activity A summary of the stock plan activity is as follows:

        Total Options Outstanding

        Weighted-AverageExercise Price

        Weighted-Average Remaining Contractual Life (in years)

        Aggregate Intrinsic Value(in thousands)

        Outstanding at December 31, 2023

        3,930,306

        $
        10.86

        8.14

        $
        37,853

        Granted

        1,700,899

        2.42

        Exercised

        (28,930
        )

        7.78

        Forfeited/expired

        (711,432
        )

        8.91

        Vested and expected to vest at December 31, 2024

        4,890,843

        $
        8.23

        6.66

        $
        330

        Exercisable as of December 31, 2024

        2,883,622

        $
        9.45

        5.46

        $
        263

      As of December 31, 2024, there was unrecognized stock-based compensation expense of $8.3 million related to unvested stock options which the Company expects to recognize over a weighted-average period of 1.6 years.Weighted-average grant-date fair value of the options granted during the year ended December 31, 2024 was $2.05 per share.RSU ActivityRSUs entitle the holder to receive shares of the Company’s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company